Dark | Light
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![Quantumup1 Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1060595604022280192.png) quantumup [@Quantumup1](/creator/twitter/Quantumup1) on x 3524 followers
Created: 2025-07-07 11:46:48 UTC

Stifel reiterated $LXEO Buy-$21.
$SLNO $BIIB $LRMR $PTCT $SRPT
Stifel said in its note:  " $LXEO announced that they received Breakthrough Designation for LX2006 in FA-CM -- the company also disclosed that they've been selected to participate in a CMC pilot program to expedite timelines, and they're actively working with FDA to finalize an SAP for their pivotal trial, where they remain on-track to start in early-2026.

Recall, earlier this year $LXEO shared that following an RMAT Type-B meeting, they aligned on a registrational study with an external control (currently enrolling patients) along with co-primary endpoints that we view as favorable/a reasonably-low bar based on prior ph1/2 data (≥10% reduction in LVMI from baseline and any increase in baseline FXN via LCMS).

Most importantly, we view receipt of BTD here after the FDA has reviewed clinical data to be a bullish sign for their regulatory prospects -- of note this also occurred for $SLNO in PWS -- and continuing to show that for rare/GTx, FDA may continue to remain flexible/accommodating."


XXXXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1942188548423066074/c:line.svg)

**Related Topics**
[fxn](/topic/fxn)
[aav](/topic/aav)
[pdf](/topic/pdf)
[sap](/topic/sap)
[$7846t](/topic/$7846t)
[breakthrough](/topic/breakthrough)
[$srpt](/topic/$srpt)
[$lrmr](/topic/$lrmr)

[Post Link](https://x.com/Quantumup1/status/1942188548423066074)

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

Quantumup1 Avatar quantumup @Quantumup1 on x 3524 followers Created: 2025-07-07 11:46:48 UTC

Stifel reiterated $LXEO Buy-$21. $SLNO $BIIB $LRMR $PTCT $SRPT Stifel said in its note: " $LXEO announced that they received Breakthrough Designation for LX2006 in FA-CM -- the company also disclosed that they've been selected to participate in a CMC pilot program to expedite timelines, and they're actively working with FDA to finalize an SAP for their pivotal trial, where they remain on-track to start in early-2026.

Recall, earlier this year $LXEO shared that following an RMAT Type-B meeting, they aligned on a registrational study with an external control (currently enrolling patients) along with co-primary endpoints that we view as favorable/a reasonably-low bar based on prior ph1/2 data (≥10% reduction in LVMI from baseline and any increase in baseline FXN via LCMS).

Most importantly, we view receipt of BTD here after the FDA has reviewed clinical data to be a bullish sign for their regulatory prospects -- of note this also occurred for $SLNO in PWS -- and continuing to show that for rare/GTx, FDA may continue to remain flexible/accommodating."

XXXXX engagements

Engagements Line Chart

Related Topics fxn aav pdf sap $7846t breakthrough $srpt $lrmr

Post Link

post/tweet::1942188548423066074
/post/tweet::1942188548423066074